Conference Proceedings

After a relapse, patients who switch to natalizumab have better outcomes than those who switch between platform therapies

M Trojano, T Spelman, T Kalincik, A Zhang, H Wiendl, L Kappos, S Belachew, R Hyde, F Verheul, F Grand-Maison, G Izquierdo, H Butzkueven

EUROPEAN JOURNAL OF NEUROLOGY | WILEY-BLACKWELL | Published : 2014